Skip to content
Triangle logo TriangleGet started
← Study library

NCT00546377 · REGISTRY CONDITION SEARCH

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2016-05-12

RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving pentostatin together with combination chemotherapy and rituximab may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of mitoxantrone when given together with pentostatin, cyclophosphamide, and rituximab and to see how well it works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response

→

outcome · POSTED

Maximum Tolerated Dose (MTD) of Mitoxantrone

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following diseases confirmed by a Memorial Sloan-Kettering Cancer Center (MSKCC) pathologist: * Chronic lymphocytic leukemia meeting the following risk criteria as defined by the three-stage Rai system: * Intermediate-risk disease meeting the following criteria for active disease as defined by the NCI Working Group: * Weight loss * Fatigue * Fevers * Evidence of progressive marrow failure * Splenomegaly * Progressive lymphadenopathy * Progressive lymphocytosis with a rapid doubling time, defined as doubling time less than 6 months and absolute lymphocyte count \> 30,000/μL * High-risk disease * Other low grade B-cell neoplasms, including any of the following: * Small lymphocytic lymphoma * Follicular lymphoma * Waldenstrom macroglobulinemia * Marginal zone lymphomas * Mantle cell lymphomas * Transformed lymphoma * Previously treated disease * Must have received prior cytotoxic therapy * Malignant lymphocytes must demonstrate B-cells via immunophenotypic or immunohistochemical analysis NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: * Karnofsky performance status 60-100% * Life expectancy \> 8 weeks * Total bilirubin ≤ 2.0 mg/dL (patients with Gilbert disease or autoimmune hemolytic anemia should have an evaluation for other causes of hyperbilirubinemia, but if none are found, may be enrolled regardless of serum bilirubin) * Total creatinine ≤ 2.0 mg/dL OR creatinine clearance \> 50 mL/min * Not pregnant or nursing * Fertile patients must use effective contraception * Normal cardiac ejection fraction ≥ 50% (increased ejection fraction \[at least 5% over rest\]) required for study eligibility * Borderline (40-50%) ejection fraction must undergo a stress echocardiogram or MUGA scan * Patients with autoimmune hemolytic anemia or autoimmune thrombocytopenia are eligible for treatment * Must have undergone consultation with the primary investigator or his/her designee prior to study entry * No significant active infections * No ongoing hepatitis B infection, specifically hepatitis B antigen or surface antigen positivity * Hepatitis B antibody-positive patients are eligible PRIOR CONCURRENT THERAPY: * See Disease Characteristics * The following concurrent medications are allowed: * Intravenous immunoglobulin (IVIG) * Erythropoietin, darbepoetin, filgrastim, or sargramostim * Cyclosporine (only for patients with cellular immune cytopenias \[i.e., pure red cell aplasia\]), with required consultation of the principle investigator or designee * Concurrent prednisone allowed provided it is used as brief courses (≤ 7 days) for inflammatory conditions unrelated to CLL * No concurrent chemotherapy or radiotherapy
healthy Volunteers
false
maximum Age
120 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. intervention Names
    1. Biological: filgrastim
    2. Biological: pegfilgrastim
    3. Biological: rituximab
    4. Biological: sargramostim
    5. Drug: cyclophosphamide
    6. Drug: mitoxantrone hydrochloride
    7. Drug: pentostatin
    8. Genetic: fluorescence in situ hybridization
    9. Genetic: gene rearrangement analysis
    10. Genetic: polymerase chain reaction
    11. Genetic: protein expression analysis
    12. Other: flow cytometry
    label
    Mitoxantrone
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Mitoxantrone
    name
    filgrastim
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Mitoxantrone
    name
    pegfilgrastim
    type
    BIOLOGICAL
  3. arm Group Labels
    1. Mitoxantrone
    name
    rituximab
    type
    BIOLOGICAL
  4. arm Group Labels
    1. Mitoxantrone
    name
    sargramostim
    type
    BIOLOGICAL
  5. arm Group Labels
    1. Mitoxantrone
    name
    cyclophosphamide
    type
    DRUG
  6. arm Group Labels
    1. Mitoxantrone
    name
    mitoxantrone hydrochloride
    type
    DRUG
  7. arm Group Labels
    1. Mitoxantrone
    name
    pentostatin
    type
    DRUG
  8. arm Group Labels
    1. Mitoxantrone
    name
    fluorescence in situ hybridization
    type
    GENETIC
  9. arm Group Labels
    1. Mitoxantrone
    name
    gene rearrangement analysis
    type
    GENETIC
  10. arm Group Labels
    1. Mitoxantrone
    name
    polymerase chain reaction
    type
    GENETIC
  11. arm Group Labels
    1. Mitoxantrone
    name
    protein expression analysis
    type
    GENETIC
  12. arm Group Labels
    1. Mitoxantrone
    name
    flow cytometry
    type
    OTHER
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
50
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Complete response (CR): Absence of lymphadenopathy, hepatomegaly or splenomegaly by physical examination and appropriate radiographic techniques (if abnormal pre-treatment): it is recognized that some patients with lymphoid malignancies who achieve a CR may have mild persistent abnormalities on CT Scan. Such abnormalities if stable on subsequent scanning will not be viewed as persistent disease in patients who otherwise meet the criteria for CR. Response will be assessed on an ongoing basis, but at a minimum of prior to cycle four and following completion of all therapy. Patients who are removed from study early will have response status determined at time of removal from study. The major criteria for determination of response to therapy in patients with CLL include physical examination and examination of the peripheral blood and bone marrow. Radiographic studies are not required but those that were abnormal pre-treatment, will be repeated to document the degree of maximal response.
    measure
    Overall Response
    time Frame
    3 years
  2. description
    The MTD is defined as the highest dose studied for which the incidence of DLT is less than 33%. In the phase I portion of the trial, cohorts of 3-6 pts will receive pentostatin, cyclophosphamide and rituximab along with one of three potential dose levels of mitoxantrone. The following dose escalation scheme will be followed: If none of the initial three pts in a cohort experience a dose-limiting toxicity (grade 4 infection, or grade ≥ 3 non-hematologic toxicity that persists for 7 days or more) then a new cohort of three pts will be treated at the next higher dose level. If one of the three pts in a cohort experiences DLT, then up to three additional pts will be treated at the same dose level. If two or more pts in a cohort experience DLT, then the maximum tolerated dose (MTD) will have been exceeded, and no further dose escalation will occur. The previous dose level will be considered as the MTD.
    measure
    Maximum Tolerated Dose (MTD) of Mitoxantrone
    time Frame
    2 years
Full study description
brief Summary
RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving pentostatin together with combination chemotherapy and rituximab may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of mitoxantrone when given together with pentostatin, cyclophosphamide, and rituximab and to see how well it works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell cancer.
detailed Description
OUTLINE: This is a phase I, dose-escalation study of mitoxantrone hydrochloride followed by a phase II study. * Phase I: Patients receive pentostatin IV, cyclophosphamide IV, and mitoxantrone hydrochloride IV on day 1. Patients also receive rituximab IV on day 1 beginning in course 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. * Phase II: Patients receive pentostatin, cyclophosphamide, rituximab, and mitoxantrone hydrochloride (at the maximum tolerated dose determined in phase I) as in phase I. All patients receive either pegfilgrastim subcutaneously (SC) on days 1-4 following each course or filgrastim or sargramostim SC beginning 2 days after each course until blood counts recover. Patients undergo blood collection and bone marrow biopsy periodically for assessment of therapy response by biomarker and laboratory studies. Samples are analyzed for molecular genetics for IgH arrangement by PCR and for response by immunoelectrophoresis. Some samples are analyzed for response by flow cytometry or fluorescence in situ hybridization (FISH). After completion of study treatment, patients are followed every 3 months for 1 year. PROJECTED ACCRUAL: A total of 63 patients (18 patients for phase I and 45 patients for phase II) will be accrued for this study.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-0162df46275e279b3b92
      requested nct id
      NCT00546377
      primary nct id
      NCT00546377
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      61c4a9702459e8d5d8fe4e1df245db3a3ff3114cfe37d0812b16773a8e615311
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-0162df46275e279b3b92
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00546377
      occurrences
      1. context exact
        NCT00546377
        end
        11
        exact text
        NCT00546377
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/144/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      f8bbf326324c78ca6876c78df477e2f65b36b967447e9e2a8946fb1402ff1e05

    Preserved source evidence · Not medical advice